Lenvatinib: A Powerful Anti-Cancer Medication for Thyroid, Kidney & Liver Cancer
Lenvatinib, widely recognised under various brand names, including Beacon Pharmaceutical PLC, is a potent anti-cancer medication used to treat several aggressive cancers. Developed by Eisai Co., Lenvatinib functions as a multiple kinase inhibitor, targeting key cancer-related proteins like VEGFR1, VEGFR2, VEGFR3, and others.
Approved Medical Uses
Since its FDA approval in 2015, Lenvatinib has been a go-to treatment for:
- Differentiated Thyroid Cancer (DTC): Effective against progressive, radioiodine-refractory thyroid cancer.
- Advanced Renal Cell Carcinoma (RCC): Used in combination with Everolimus for patients previously treated with anti-angiogenic therapy.
- Hepatocellular Carcinoma (HCC): Approved for first-line treatment of unresectable liver cancer in patients without prior systemic therapy.
Potential Side Effects
Common adverse effects observed include:
- High Blood Pressure (Hypertension) – Seen in 73% of patients
- Diarrhoea & Fatigue – Affecting around 67%
- Nausea, Appetite Loss & Muscle Pain
- Thrombocytopenia (Low Blood Platelets)
Patients should consult healthcare providers for a comprehensive risk assessment.
Mechanism & Pharmacology
Lenvatinib works by blocking multiple kinase pathways, particularly those involved in cancer growth and angiogenesis. The drug is quickly absorbed, reaching peak plasma levels within 1-4 hours, with high bioavailability (85%).
History & Global Approvals
- 2006 – Phase I trial initiated for cancer patients.
- 2012-2013 – Granted Orphan Drug Status in the US, Japan, & Europe.
- 2015 – FDA & EMA approval for thyroid cancer treatment.
- 2016-2018 – Expanded approvals for kidney & liver cancer treatment.
Lenvatinib continues to be a leading targeted therapy for various cancers, improving patient outcomes worldwide.
